Patents Assigned to Nektar Therapeutics
  • Method for Assessing and Predicting Efficacy of Breast Cancer Treatment with a Long-Acting Topoisomerase I Inhibitor
    Publication number: 20150309032
    Abstract: Provided is a method of treating an individual suffering from a cancer such as breast cancer by administering to the individual a long-acting topoisomerase I inhibitor such as SN-38 or irinotecan, and correlating the level of at least one tumor marker such as CA27.29 in the individual with response of the cancer to treatment with the long-acting topoisomerase I inhibitor, to thereby provide a method for predicting and assessing the therapeutic efficacy of the treatment.
    Type: Application
    Filed: November 27, 2013
    Publication date: October 29, 2015
    Applicant: NEKTAR THERAPEUTICS
    Inventors: Yen Lin CHIA, Ute HOCH, Alison HANNAH, Michael A. ELDON
  • N-maleimidyl polymer derivatives
    Patent number: 9169350
    Abstract: The invention is directed to multi-functional N-maleimidyl polymer derivatives comprising a water soluble and non-peptidic polymer backbone having a terminal carbon, such as a poly(alkylene glycol), the terminal carbon of the polymer backbone being directly bonded to the nitrogen atom of a N-maleimidyl moiety without a linking group therebetween. The invention also provides two methods of preparing such linkerless N-maleimidyl polymer derivatives.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: October 27, 2015
    Assignee: Nektar Therapeutics
    Inventor: Xiaoming Shen
  • Oligomer-dantrolene conjugates and related compounds
    Patent number: 9168311
    Abstract: The invention relates to (among other things) oligomer-dantrolene conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered compounds.
    Type: Grant
    Filed: August 20, 2013
    Date of Patent: October 27, 2015
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Wen Zhang
  • Oligomer-cannabinoid conjugates
    Patent number: 9155797
    Abstract: The invention relates to (among other things) oligomer-cannabinoid conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated cannabinoid compounds.
    Type: Grant
    Filed: July 22, 2014
    Date of Patent: October 13, 2015
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, C. Simone Jude-Fishburn, Guy Lalonde
  • Solid Salt Form of Alpha-6-MPEG6-O-Hydroxycodone as Opioid Agonists and Uses Thereof
    Publication number: 20150284402
    Abstract: Solid forms of certain opioid agonists are provided herein. Methods of preparing the solid forms, methods of using the solid forms, and pharmaceutical compositions comprising the solid forms are also provided herein.
    Type: Application
    Filed: October 29, 2013
    Publication date: October 8, 2015
    Applicant: Nektar Therapeutics
    Inventors: Patricia Andres, Yogesh Datar, Ramakrishna Gadiraju, Bruce Andrew Kowalczyk, Gabriel Christian Kuklis, Mahmoud Mirmehrabi, Nicholas Paschalides
  • NEGATIVELY BIASED SEALED NEBULIZER SYSTEMS AND METHODS
    Publication number: 20150283336
    Abstract: Methods, systems, and devices are described for creating a negative bias pressure within a liquid reservoir. Embodiments may include providing a liquid reservoir coupled with an aerosol generator. The liquid reservoir may be sealed to create the sealed reservoir. An ambient pressure may be maintained while the liquid reservoir is being sealed and the ambient pressure may be maintained in the sealed liquid reservoir until a portion of the liquid is dispensed. Further, embodiments may include vibrating the aperture plate to dispense the portion of the liquid. The portion of the liquid dispensed may decreases the amount of the liquid in the sealed reservoir. By decreasing the amount of liquid in the sealed reservoir, a negative bias pressure between an air side and a liquid side of the aperture plate may be created.
    Type: Application
    Filed: June 17, 2015
    Publication date: October 8, 2015
    Applicant: NEKTAR THERAPEUTICS
    Inventors: David Mark Blakey, Richard Francis Day
  • Crystalline naloxol-PEG conjugate
    Patent number: 9149539
    Abstract: Naloxol-polyethylene glycol conjugates of the formula: are provided in oxalate or phosphate salt forms including crystalline forms. Methods of preparing the salt forms and pharmaceutical compositions comprising the salt forms are also provided.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: October 6, 2015
    Assignees: ASTRAZENECA AB, NEKTAR THERAPEUTICS
    Inventors: Bengt Aslund, Carl-Johan Aurell, Martin Hans Bohlin, Tesfai Sebhatu, Bo Ingvar Ymen, Eric Thomas Healy, David Richard Jensen, David Thomas Jonaitis, Stephan Parent
  • Systems and methods for driving sealed nebulizers
    Patent number: 9149588
    Abstract: Various methods, devices, and systems are described for aerosolizing a liquid. Embodiments may include sealing the liquid within a reservoir. An output waveform signal may be generated. A nebulizer element may be vibrated to aerosolize the liquid. A negative pressure may be produced within the reservoir as the liquid is aerosolized. The output waveform signal may cause the nebulizer element to vibrate. Embodiments may involve determining a phase shift between a current of the output waveform signal and a voltage of the output waveform signal. Also, embodiments may involve adjusting a frequency of the output waveform signal at least partially based on the phase shift. Further, embodiments may involve adjusting the voltage of the output waveform signal at least partially based on the frequency of the output waveform signal.
    Type: Grant
    Filed: July 19, 2010
    Date of Patent: October 6, 2015
    Assignee: NEKTAR THERAPEUTICS
    Inventors: Benjamin Morris Gordon, Steven David Gardner, Matthew James Hayes
  • Oligomer conjugates of heteropentacyclic nucleosides
    Patent number: 9149538
    Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: October 6, 2015
    Assignee: Nektar Therapeutics
    Inventors: Bo-Liang Deng, Timothy A. Riley, Jennifer Riggs-Sauthier
  • Aerosolization device
    Patent number: 9144650
    Abstract: An aerosol transfer device for medical aerosol generators includes a body, fluidically coupled to a nebulizer and to a patient interface. An ambient air intake is formed into a lower body. The body is shaped and configured to optimize mixing of ambient air from the ambient air intake and the aerosol generated by the nebulizer, resulting in the formation of an aerosol plume having optimum characteristics for delivery of the aerosol to the patient's pulmonary system, such as the central or deep lung regions. The shape and dimensions of the body are further designed to minimize aerosol deposition, thus improving delivery efficiency.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: September 29, 2015
    Assignee: Nektar Therapeutics
    Inventors: James B. Fink, Nani P. Kadrichu
  • Oligomer-calcium channel blocker conjugates
    Patent number: 9132200
    Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the small molecule drug not attached to the water soluble oligomer.
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: September 15, 2015
    Assignee: Nektar Therapeutics
    Inventors: Zhongxu Ren, Bo-Liang Deng, Jennifer Riggs-Sauthier, Micah Harvey
  • Oligomer-Containing Benzamide-Based Compounds
    Publication number: 20150250894
    Abstract: The invention relates to (among other things) oligomer-containing benzamide-based compounds. A compound of the invention exhibits one or more advantages over corresponding compounds lacking the oligomer.
    Type: Application
    Filed: September 17, 2013
    Publication date: September 10, 2015
    Applicant: Nektar Therapeutics
    Inventors: Lin Cheng, Jennifer Riggs-Sauthier, Neel K. Anand
  • Oligomer-anticholinergic agent conjugates
    Patent number: 9126926
    Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different as compared to the characteristics of the small molecule drug not attached to the water-soluble oligomer.
    Type: Grant
    Filed: February 1, 2013
    Date of Patent: September 8, 2015
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Bo-Liang Deng
  • Compositions of particulate coformulation
    Patent number: 9120031
    Abstract: Embodiments of the invention provide a composition of a particulate coformulation which includes particles containing an active substance and an additive, wherein each particle contains a relative additive concentration increasing radially outwards from a particle center to a particle surface along a finite gradient. In one example, the particle surface is an additive-rich surface without a distinct physical boundary between the particle center and the particle surface. The relative additive concentration may have a continuous rate of change across the finite gradient. In some examples, an active substance: additive ratio of the particle surface is sufficiently low to form a protective surface layer around the active substance. Generally, the particle surface is free of the active substance.
    Type: Grant
    Filed: July 17, 2006
    Date of Patent: September 1, 2015
    Assignee: NEKTAR THERAPEUTICS
    Inventors: Mazen H. Hanna, Peter York
  • Oligomer-protease inhibitor conjugates
    Patent number: 9107956
    Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the small molecule drug not attached to the water-soluble oligomer.
    Type: Grant
    Filed: October 16, 2013
    Date of Patent: August 18, 2015
    Assignee: NEKTAR THERAPEUTICS
    Inventors: Jennifer Riggs-Sauthier, Lin Cheng, Tacey X. Viegas, Xuyuan Gu, Franco J. Duarte, Wen Zhang
  • Vibration systems and methods
    Patent number: 9108211
    Abstract: In one arrangement, a vibration system includes a vibratable plate, a support member surrounding the vibratable plate, and a vibration-inducing member surrounding the support member. The vibration-inducing member is configured to radially expand and contract against the support member so as to produce axial vibration of the vibratable plate. In another arrangement, the vibratable plate has an outer circumference; a tubular member is concentrically disposed about the outer circumference of the plate, and an annular vibration-inducing member is concentrically disposed about the outer circumference of the tubular member. The vibration-inducing member is preferably a piezoelectric ring that is radially expandable and contractable against the wall of the tubular member to cause the plate to vibrate in the axial direction.
    Type: Grant
    Filed: April 17, 2006
    Date of Patent: August 18, 2015
    Assignee: Nektar Therapeutics
    Inventor: Yehuda Ivri
  • Conjugates of an anti-TNF-? antibody
    Patent number: 9101670
    Abstract: Conjugates of an anti-TNF antibody and one or more nonpeptidic water soluble polymers are provided. Typically, the nonpeptidic water soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, and methods of administering compositions to a patient.
    Type: Grant
    Filed: April 6, 2007
    Date of Patent: August 11, 2015
    Assignee: Nektar Therapeutics
    Inventors: Mary J. Bossard, Gayle Stephenson
  • Oligomer-protein tyrosine kinase inhibitor conjugates
    Patent number: 9095622
    Abstract: The invention relates to (among other things) oligomer-PTK inhibitor conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over PTK inhibitor compounds lacking a water-soluble, non-peptidic oligomer.
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: August 4, 2015
    Assignee: NEKTAR THERAPEUTICS
    Inventors: Jennifer Riggs-Sauthier, Wen Zhang
  • Oligome-bis-chromonyl compound conjugates
    Patent number: 9095621
    Abstract: The invention provides oligomer-bis-chromonyl compound conjugates. The conjugates of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered compounds.
    Type: Grant
    Filed: April 23, 2009
    Date of Patent: August 4, 2015
    Assignee: NEKTAR THERAPEUTICS
    Inventors: Jennifer Riggs-Sauthier, Bo-Liang Deng
  • Reagents
    Patent number: 9095620
    Abstract: Oligomeric reagents are provided comprising a moiety of atoms arranged in a specific order, wherein the moiety is positioned between a water-soluble, non-peptidic oligomer and a pharmaceutically active agent. The oligomeric reagents are useful for, among other things, forming oligomer active agent conjugates. Related methods, compositions, preparations, and so forth are also provided.
    Type: Grant
    Filed: March 12, 2009
    Date of Patent: August 4, 2015
    Assignee: NEKTAR THERAPEUTICS
    Inventor: Franco J. Duarte